Eledon Pharmaceuticals is a pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat. Co. has two platform technologies, a surfactant and a foam. Co.'s primary program, OP0201, is a surfactant-based nasal aerosol drug-device combination product candidate being developed as a treatment option for patients at risk for, or with, otitis media (OM). OM is defined as middle ear inflammation and effusion with or without infection. Co. also has a foam-based drug delivery technology platform, which may be developed to deliver drugs into the ear, nasal, and sinus cavities. The ELDN stock yearly return is shown above.
The yearly return on the ELDN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ELDN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|